Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Bortezomib Inhibits Expression of TGF-β1, IL-10, and CXCR4, Resulting in Decreased Survival and Migration of Cutaneous T Cell Lymphoma Cells
Tzu‐Pei Chang, Vladimir Poltoratsky, Ivana Vancurova
The Journal of Immunology (2015) Vol. 194, Iss. 6, pp. 2942-2953
Open Access | Times Cited: 44

Showing 26-50 of 44 citing articles:

Cell signaling in cutaneous T‐cell lymphoma microenvironment: promising targets for molecular‐specific treatment
Natalia Rendón‐Serna, Luis Alfonso Correa Londoño, Margarita María Velásquez‐Lopera, et al.
International Journal of Dermatology (2021) Vol. 60, Iss. 12, pp. 1462-1480
Closed Access | Times Cited: 16
Novel phosphorylated TAK1 species with functional impact on NF-κB and β-catenin signaling in human Cutaneous T-cell lymphoma
Fernando Gallardo, Joan Bertran, Erika López‐Arribillaga, et al.
Leukemia (2018) Vol. 32, Iss. 10, pp. 2211-2223
Open Access | Times Cited: 18
Suppressors of Cytokine Signaling (SOCS)1 and SOCS3 Proteins Are Mediators of Interleukin-10 Modulation of Inflammatory Responses Induced byChlamydia muridarumand Its Major Outer Membrane Protein (MOMP) in Mouse J774 Macrophages
Skyla A. Duncan, Rajnish Sahu, Saurabh Dixit, et al.
Mediators of Inflammation (2020) Vol. 2020, pp. 1-29
Open Access | Times Cited: 16
Cutaneous localization in multiple myeloma in the context of bortezomib-based treatment: how do myeloma cells escape from the bone marrow to the skin?
Valentina Marchica, Fabrizio Accardi, Paola Storti, et al.
International Journal of Hematology (2016) Vol. 105, Iss. 1, pp. 104-108
Closed Access | Times Cited: 15
Innovative Treatment Concepts for Cutaneous T-Cell Lymphoma Based on Microenvironment Modulation
Katharina Leuchte, Max Schlaak, Rudolf Stadler, et al.
Oncology Research and Treatment (2017) Vol. 40, Iss. 5, pp. 262-269
Open Access | Times Cited: 14
Chemo-free salvage treatment outperforms traditional chemotherapy in advanced lines of relapsed/refractory subcutaneous panniculitis-like T-cell lymphoma
Chao Chen, Jingjing Yin, Minghui Duan, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 1
CCR10/CCL27 crosstalk contributes to failure of proteasome-inhibitors in multiple myeloma
Shanmugapriya Thangavadivel, Claudia Zelle‐Rieser, Angelika Olivier, et al.
Oncotarget (2016) Vol. 7, Iss. 48, pp. 78605-78618
Open Access | Times Cited: 7
Curcumin in combination with homoharringtonine suppresses lymphoma cell growth by inhibiting the TGF-β/Smad3 signaling pathway
Yu Zhang, Jingjing Xiang, Ni Zhu, et al.
Aging (2021) Vol. 13, Iss. 14, pp. 18757-18768
Open Access | Times Cited: 7
Apoptosis Induction and Gene Expression Profile Alterations of Cutaneous T-Cell Lymphoma Cells following Their Exposure to Bortezomib and Methotrexate
Vassiliki Mpakou, Evangelia Papadavid, Frieda Kontsioti, et al.
PLoS ONE (2017) Vol. 12, Iss. 1, pp. e0170186-e0170186
Open Access | Times Cited: 5
Molecular basis of targeted therapy in T/NK-cell lymphoma/leukemia: A comprehensive genomic and immunohistochemical analysis of a panel of 33 cell lines
R. Mondéjar, Cristina Fernández, Arantza Onaindía, et al.
PLoS ONE (2017) Vol. 12, Iss. 5, pp. e0177524-e0177524
Open Access | Times Cited: 5
New Molecular and Biological Markers in Cutaneous T Cell Lymphoma: Therapeutic Implications
Daniel E. Luna, Michi M. Shinohara
Current Hematologic Malignancy Reports (2023) Vol. 18, Iss. 3, pp. 83-88
Closed Access | Times Cited: 2
Cutaneous T-cell lymphoma: aetiopathogenesis and current diagnostic and therapeutic developments
Marianna Papadaki, Konstantina Saraki, Fani Karagianni, et al.
European Journal of Dermatology (2020) Vol. 30, Iss. 2, pp. 85-102
Closed Access | Times Cited: 5
Mobilization of human immature hematopoietic progenitors through combinatory use of bortezomib and immunomodulatory drugs
Taro Tochigi, Takatoshi Aoki, Yoshikane Kikushige, et al.
International Journal of Hematology (2016) Vol. 105, Iss. 4, pp. 423-432
Closed Access | Times Cited: 2
Progress in understanding of relationship between inflammation and tumors
Zhao-Chun Chi
Shijie huaren xiaohua zazhi (2024) Vol. 32, Iss. 1, pp. 23-40
Open Access
DMF: a promising therapeutic option in CTCL
Ivana Vancurova
Blood (2016) Vol. 128, Iss. 6, pp. 745-746
Open Access | Times Cited: 1
Computational drug repositioning of bortezomib to reverse metastatic effect ofGALNT14in lung cancer
Ok‐Seon Kwon, Haeseung Lee, Hyeon‐Joon Kong, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2018)
Open Access | Times Cited: 1
[Association of interleukin-10 gene polymorphism with enterovirus 71 infection in children].
Na Zhao, Jing Li, Zhenzhen Chen, et al.
PubMed (2019) Vol. 21, Iss. 8, pp. 789-795
Closed Access | Times Cited: 1
Analysis of endogenous and exogenous tumor upregulated promoter expression in canine tumors
Abdul Mohin Sajib, Maninder Sandey, Samantha Morici, et al.
PLoS ONE (2020) Vol. 15, Iss. 11, pp. e0240807-e0240807
Open Access | Times Cited: 1
Innovative Behandlungskonzepte mit Modulation der Mikroumgebung beim kutanen T-Zell-Lymphom
Katharina Leuchte, Max Schlaak, Rudolf Stadler, et al.
Kompass Dermatologie (2019) Vol. 7, Iss. 3, pp. 111-119
Closed Access
Previous Page - Page 2

Scroll to top